Synergy Pharma: Sales Ramp Ignored
- Synergy Pharma continues a slow ramp of Turlance prescriptions.
- Significant cost controls helped cut the quarterly loss my nearly $10 million.
- The Express Scripts deal for 2019 places the biotech on a path to a huge sales ramp by Q2'19.
Synergy Pharma (SGYP) has made several rallies towards $2, but the biotech stock hasn't held any gains despite improving prescription numbers for Trulance that treats IBS. The business developments during the last few months sets the stock up for a sustainable rally.
Read the full article on Seeking Alpha.
Disclosure: Long SGYP. Please review the disclaimer page for more details.